| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Bortezomib | CTRPv2 | pan-cancer | AAC | 0.082 | 0.02 |
| mRNA | triazolothiadiazine | CTRPv2 | pan-cancer | AAC | 0.07 | 0.02 |
| mRNA | KPT185 | CTRPv2 | pan-cancer | AAC | 0.089 | 0.02 |
| mRNA | PF-3758309 | CTRPv2 | pan-cancer | AAC | 0.1 | 0.02 |
| mRNA | brivanib | CTRPv2 | pan-cancer | AAC | -0.083 | 0.02 |
| mRNA | BMS-536924 | CTRPv2 | pan-cancer | AAC | 0.083 | 0.02 |
| mRNA | BRD-K11533227 | CTRPv2 | pan-cancer | AAC | 0.086 | 0.02 |
| mRNA | procarbazine | CTRPv2 | pan-cancer | AAC | -0.091 | 0.02 |
| mRNA | GSK1070916 | GDSC1000 | pan-cancer | AAC | 0.071 | 0.02 |
| mRNA | ISOX | CTRPv2 | pan-cancer | AAC | 0.073 | 0.02 |